BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8318875)

  • 41. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
    Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
    Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
    Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A; Blessing J; Bender D; Mannel R; Morgan M;
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos HP; Efstathiou E; Salamalekis E; Farmakis D; Skarlos D; Briasoulis E; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2005 May; 97(2):436-41. PubMed ID: 15863142
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DNA adducts induced by platinum drug chemotherapeutic agents in human tissues.
    Poirier MC; Shamkhani H; Reed E; Tarone RE; Gupta-Burt S
    Prog Clin Biol Res; 1992; 374():197-212. PubMed ID: 1620704
    [No Abstract]   [Full Text] [Related]  

  • 48. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
    Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
    Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.
    Welters MJ; Fichtinger-Schepman AM; Baan RA; Jacobs-Bergmans AJ; Kegel A; van der Vijgh WJ; Braakhuis BJ
    Br J Cancer; 1999 Jan; 79(1):82-8. PubMed ID: 10408697
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
    Markman M; Federico M; Liu PY; Hannigan E; Alberts D
    Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy.
    Bedrosian I; Lee C; Tucker SL; Palla SL; Lu K; Keyomarsi K
    Clin Cancer Res; 2007 Aug; 13(16):4800-6. PubMed ID: 17699858
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Capillary electrophoretic separation and laser-induced fluorescence detection of the major DNA adducts of cisplatin and carboplatin.
    Sharma M; Jain R; Ionescu E; Slocum HK
    Anal Biochem; 1995 Jul; 228(2):307-11. PubMed ID: 8572311
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Platinum-based chemotherapy in metastatic breast cancer: current status.
    Decatris MP; Sundar S; O'Byrne KJ
    Cancer Treat Rev; 2004 Feb; 30(1):53-81. PubMed ID: 14766126
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from platinum-treated cancer patients.
    Terheggen PM; Dijkman R; Begg AC; Dubbelman R; Floot BG; Hart AA; den Engelse L
    Cancer Res; 1988 Oct; 48(19):5597-603. PubMed ID: 3046743
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DNA adducts in human and patas monkey maternal and fetal tissues induced by platinum drug chemotherapy.
    Shamkhani H; Anderson LM; Henderson CE; Moskal TJ; Runowicz CD; Dove LF; Jones AB; Chaney SG; Rice JM; Poirier MC
    Reprod Toxicol; 1994; 8(3):207-16. PubMed ID: 8075509
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Phase II study of CIS-diamminedichloroplatinum (II) by collaborative study].
    Kato T
    Gan To Kagaku Ryoho; 1982 Apr; 9(4):694-701. PubMed ID: 6892198
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
    Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
    Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.